Abstract
Background and aims
Ascertainment bias (AB) indicates a bias of an evaluation centre in estimating the prevalence/incidence of a disease due to the specific expertise of the centre. The aim of our study was to evaluate classification of different types of dementia in new cases appearing in secondary and tertiary centres, in order to evidence possible occurrence of AB in the various (secondary to tertiary) dementia centres.
Methods
To assess the mechanism of AB, the rates of new cases of the different forms of dementia reported by different centres were compared. The centres involved in the study were 11 hospital-based centres including a tertiary centre, located in the University Department of Clinical Neurology. The tertiary centre is endowed with state-of-the-art diagnostic facilities and its scientific production is prominently focused on dementia with Lewy bodies (DLB) thus suggesting the possible occurrence of a bias. Four main categories of dementia were identified: Alzheimer’s disease (AD), DLB, fronto-temporal dementia (FTD), vascular dementia (VaD), with other forms in a category apart. The classification rate of new cases of dementia in the tertiary centre was compared with rates reported by secondary centres and rates of recoding were calculated during a follow-up of 2 years.
Results
The study classified 2,042 newly diagnosed cases of dementia in a population of 1,370,000 inhabitants of which 315,000 were older than 65. AD was categorized in 48–52 % of cases, DLB in 25–28 %, FTD in 2–4 % and VaD in 17–28 %. During the 2-year follow-up the diagnosis was re-classified in 40 patients (3 %). The rate of recoding was 5 % in the tertiary centre, 2–8 % in referrals from secondary to tertiary centre, 2–10 % in recodings performed in secondary centres and addressed to tertiary centre. Recoding or percentages of new cases of AD or DLB were not different in the comparison between secondary or between secondary and tertiary centres. FTD and VaD were instead significantly recoded.
Conclusion
The results of the study suggest that in a homogeneous area, AB is not interfering with diagnosis of AD or DLB.
Similar content being viewed by others
References
Storandt M, Morris JC (2010) Ascertainment bias in the clinical diagnosis of Alzheimer disease. Arch Neurol 67:1364–1369
Erten-Lyons D, Sherbakov LO, Piccinin AM, Hofer SM, Dodge HH, Quinn JF et al (2012) Review of selected databases of longitudinal aging studies. Alzheimers Dement 8:584–589
Launer LJ, Brock DB (2004) Population-based studies of AD: message and methods: an epidemiologic view. Stat Med 23:191–197
Stanziano DC, Whitehurst M, Graham P, Roos BA (2010) A review of selected longitudinal studies on aging: past findings and future directions. J Am Geriatr Soc 58(Suppl 2):S292–S297
Tuokko H, Garrett DD, McDowell I, Silverberg N, Kristjansson B (2003) Cognitive decline in high-functioning older adults: reserve or ascertainment bias? Aging Ment Health 7:259–270
Onofrj M, Varanese S, Bonanni L. Taylor JP, Antonini A, Valente EM, Petrucci S, Stocchi F, Thomas A, Perfetti B (2013) Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. J Neurol. doi:10.1007/s00415-013-6853-y
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Snowdon DA (2003) Healthy aging and dementia: findings from the Nun study. Ann Intern Med 139:450–454
Patzwald GA, Wildt SC (2004) The use of convent archival records in medical research: the school sisters of Notre Dame archives and the nun study. Am Arch 67:86–106
SantaCruz KS, Sonnen JA, Pezhouh MK, Desrosiers MF, Nelson PT, Tyas SL (2011) Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun study and the adult changes in thought study. J Neuropathol Exp Neurol 70:832–840
Mortimer JA (2012) The Nun study: risk factors for pathology and clinical-pathologic correlations. Curr Alzheimer Res 9:621–627
World Health Organization (2011) Definition of terms. Accessed 24the June 2011
World Health Organization (2011) International classification of primary care, 2nd edn (ICPC-2). Geneva. Accessed 24th June 2011
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. 4th edn (DSM IV). American Psychiatric Association, Washington
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872
Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250–260
Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ et al (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for frontotemporal lobar degeneration. Acta Neuropathol 114:5–22
Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F et al (2010) Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer’s disease: a prospective, observational study. CNS Drugs 24:163–176
Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M (2008) EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain 131(Pt 3):690–705
Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M et al (2011) Preladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10:221–229
Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M et al (2010) Safety and efficacy of perampanel in advanced Parkinson’s disease: a randomized, placebo-controlled study. Mov Disord 25:896–905
Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S (2003) Dual dopamine agonist treatment in Parkinson’s disease. J Neurol 250(7):822–826
Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A et al (2004) Improvement of motor function in early Parkinson disease by safinamide. Neurology 63:746–748
Onofrj M, Thomas A, Iacono D, Luciano AL, Di Iorio A (2003) The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin Neuropharmacol 26:239–251
Franciotti R, Iacono D, Della PS, Pizzella V, Torquati K, Onofrj M et al (2006) Cortical rhythms reactivity in AD, LBD and normal subjects: a quantitative MEG study. Neurobiol Aging 27:1100–1109
Lanuti P, Ciccocioppo F, Bonanni L, Marchisio M, Lachmann R, Tabet N et al (2012) Amyloid-specific T-cells differentiate Alzheimer’s disease from Lewy body dementia. Neurobiol Aging 33:2599–2611
Onofrj M, Taylor JP, Monaco D, Franciotti R, Anzellotti F, Bonanni L, Onofrj V, Thomas A (2012) Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. Behav Neurol (PubMed PMID: 23242366; Epub ahead of print)
Onofrj M, Monaco D, Bonanni L, Onofrj V, Bifolchetti S, Manzoli L, Thomas A (2011) Eyelid retraction in dementia with Lewy bodies and Parkinson’s disease. J Neurol 258(8):1542–1544
Bonanni L, Franciotti R, Onofrj V, Anzellotti F, Mancino E, Monaco D, Gambi F, Manzoli L, Thomas A, Onofrj M (2010) Revisiting P300 cognitive studies for dementia diagnosis: early dementia with Lewy bodies (DLB) and Alzheimer disease (AD). Neurophysiol Clin 40(5–6):255–265
Onofrj M, Bonanni L, Manzoli L, Thomas A (2010) Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies. Neurology 74(20):1598–1606
Varanese S, Perfetti B, Monaco D, Thomas A, Bonanni L, Tiraboschi P, Onofrj M (2010) Fluctuating cognition and different cognitive and behavioural profiles in Parkinson’s disease with dementia: comparison of dementia with Lewy bodies and Alzheimer’s disease. J Neurol 257(6):1004–1011
Onofrj M, Thomas A, Tiraboschi P, Wenning G, Gambi F, Sepede G, Di Giannantonio M, Di Carmine C, Monaco D, Maruotti V, Ciccocioppo F, D’Amico MC, Bonanni L (2011) Updates on somatoform disorders (SFMD) in Parkinson’s disease and dementia with Lewy bodies and discussion of phenomenology. J Neurol Sci 310(1–2):166–171
Anzellotti F, Bonanni L, Iorio E, Di Baldassarre F, D’Andreagiovanni A, Monaco D, Thomas A, Onofrj M (2008) Delayed blink reflex in dementia with Lewy bodies is sensitive to cholinergic modulation. Clin Neuropharmacol 31(4):231–237
Onofrj M, Thomas A, Bonanni L (2007) New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins. Expert Rev Neurother 7(12):1731–1750
Bonanni L, Anzellotti F, Varanese S, Thomas A, Manzoli L, Onofrj M (2007) Delayed blink reflex in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 78(10):1137–1139
Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55:1621–1626
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314
Law LL, Barnett F, Yau MK, Gray MA (2012) Measures of everyday competence in older adults with cognitive impairment: a systematic review. Age Ageing 41:9–16
Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Van BC et al (2012) Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 79:659
Ballard C, O’Brien J, Gray A, Cormack F, Ayre G, Rowan E et al (2001) Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol 58:977–982
Ballard CG, Aarsland D, McKeith I, O’Brien J, Gray A, Cormack F et al (2002) Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59:1714–1720
Jurica PJ, Leitten CL, Mattis S (2001) DRS-2 dementia rating scale 2. In: Odessa FI (ed) Psychological assessment resources
Cromwell DA, Eagar K, Poulos RG (2003) The performance of instrumental activities of daily living scale in screening for cognitive impairment in elderly community residents. J Clin Epidemiol 56:131–137
Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51:768–774
Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141:1356–1364
Buck PO, Trautman H, Clark J (2010) Scales for assessing nonmotor symptom severity changes in Parkinson’s disease patients with symptom fluctuations. Int J Neurosci 120:523–530
Carlesimo GA, Perri R, Caltagirone C (2011) Category cued recall following controlled encoding as a neuropsychological tool in the diagnosis of Alzheimer’s disease: a review of the evidence. Neuropsychol Rev 21:54–65
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699
Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139:1136–1139
Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296
Miletin MS, Hanly PJ (2003) Measurement properties of the Epworth sleepiness scale. Sleep Med 4:195–199
Groger A, Bender B, Wurster I, Chadzynski GL, Klose U, Berg D (2013) Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. J Neurol Neurosurg Psychiatry 84:644–649
Berg D, Steinberger JD, Warren OC, Naidich TP, Yousry TA (2011) Milestones in magnetic resonance imaging and transcranial sonography of movement disorders. Mov Disord 26:979–992
Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V et al (2013) EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 20:16–34
Lin LI (1989) A concordance correlation coefficient to evaluate reproducibility. Biometrics 45:255–268
Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J (2008) Metan: fixed- and random-effects meta-analysis. Stata J 8:3–28
Claassen DO, Parisi JE, Giannini C, Boeve BF, Dickson DW, Josephs KA (2008) Frontotemporal dementia mimicking dementia with Lewy bodies. Cogn Behav Neurol 21:15763
Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J (2006) What best differentiates Lewy body from Alzheimer’s disease in early stage dementia? Brain 129:729–735
Wallin MT, Kurtzke JF (2004) Neuroepidemiology. In: Bradley WG, Daroff RB, Fenichel GM (eds) Neurology in clinical practice. Butterworth Heinemann, Philadelphia, pp 763–779
Solfrizzi V, Panza F, Colacicco AM, D’Introno A, Capurso C, Torres F et al (2004) Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 63:1882–1891
Solfrizzi V, Capurso C, D’Introno A, Colacicco AM, Gagliardi G, Nicoletti A, Santamato A, Scafato E, Capurso A, Panza F (2007) Italian Longitudinal Study on Aging Working Group. Change of diagnoses in probable and possible mild cognitive impairment: the Italian longitudinal study on aging. J Am Geriatr Soc 55(9):1480–1482
Aarsland D, Ballard CG (2012) Biomarkers for dementia diagnosis: differentiating DLB and FTD may be difficult. J Neurol Neurosurg Psychiatry 83:1037
Schneider JA, Watts RL, Gearing M, Brewer RP, Mirra SS (1997) Corticobasal degeneration: neuropathologic and clinical heterogeneity. Neurology 48:959–969
Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF et al (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68:812–819
Kolasinski J, Stagg CJ, Chance SA, Deluca GC, Esiri MM, Chang EH et al (2012) A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain 135:2938–2951
Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O (2011) Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov Disord 26(8):1428–1435
McMillan CT, Avants B, Irwin DJ, Toledo JB, Wolk DA, Van D, V et al (2013) Can MRI screen for CSF biomarkers in neurodegenerative disease? Neurology 80:132–138
Acknowledgments
This study was partly founded by the UNIVA (Unità Valutazione Alzheimer Network Italia) project.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Authors are in alphabetical order for the Abruzzo Dementia Study Group.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Bonanni, L., Bontempo, G., Borrelli, I. et al. Ascertainment bias in dementias: a secondary to tertiary centre analysis in Central Italy and conceptual review. Aging Clin Exp Res 25, 265–274 (2013). https://doi.org/10.1007/s40520-013-0039-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40520-013-0039-4